Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Purchases 31,000 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 31,000 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was acquired at an average cost of $8.88 per share, for a total transaction of $275,280.00. Following the completion of the purchase, the director directly owned 16,794,043 shares in the company, valued at approximately $149,131,101.84. This represents a 0.18% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, June 26th, Ra Capital Management, L.P. purchased 1,876 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.98 per share, with a total value of $16,846.48.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.57 per share, for a total transaction of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Trading Down 0.4%

Shares of ARTV stock opened at $9.58 on Tuesday. Artiva Biotherapeutics, Inc. has a twelve month low of $1.48 and a twelve month high of $14.53. The company’s 50-day moving average price is $9.35 and its 200-day moving average price is $6.62. The stock has a market cap of $236.82 million, a price-to-earnings ratio of -2.71 and a beta of 2.40.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, equities research analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several large investors have recently made changes to their positions in ARTV. Bank of America Corp DE lifted its stake in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares in the last quarter. Prelude Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at $41,000. Dimensional Fund Advisors LP purchased a new stake in shares of Artiva Biotherapeutics in the 1st quarter valued at $131,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Artiva Biotherapeutics in the 4th quarter valued at $91,000. Finally, Sanctuary Advisors LLC acquired a new position in Artiva Biotherapeutics during the 1st quarter worth about $139,000.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Wedbush raised their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. HC Wainwright upped their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.